Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 16/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 14/20 | 0.58 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.58 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.55 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6108511 | 0.98 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL920191 | 0.83 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL6806463 | 0.83 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3155682 | 0.81 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3216528 | 0.81 | POLB (0.55) | L3MBTL3L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL920485 | 0.81 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL27598275 | 0.80 | L3MBTL3 (0.60) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL14899995 | 0.80 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL1400926 | 0.80 | L3MBTL3 (0.45) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL5779438 | 0.80 | L3MBTL3 (0.55) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023193789-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2023-10-12 | — | — | WO | claimed |
| CN-110105344-A | A kind of compound and its synthetic method and application | 北京大学 | 2019-08-09 | — | — | CN | claimed |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | claimed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | claimed |
| US-20020151501-A1 | Compounds having growth hormone releasing activity | BOWERS CYRIL Y (US) | 2002-10-17 | — | — | US | claimed |
| EP-1159292-A2 | COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | Administrators of The Tulane Educational Fund (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000009537-A2 | COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2000-02-24 | — | — | WO | claimed |
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | Illudent, Inc. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-12269793-B2 | Affinity illudofulvene conjugates | AF CHEMICALS, LLC (US) | 2025-04-08 | — | — | US | disclosed |
| CN-114728917-B | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| US-7250399-B2 | Compounds having growth hormone releasing activity | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2007-07-31 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-6468974-B1 | OLIGOPEPTIDES THAT PROVIDE DESIRABLE IN VITRO AND IN VIVO GROWTH HORMONE RELEASING ACTIVITY AND HAVE AT LEAST ONE OTHER DESIRABLE BIOLOGICAL ACTIVITY SUCH AS INCREASED RETENTION TIME | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2002-10-22 | — | — | US | disclosed |
| US-20020151501-A1 | Compounds having growth hormone releasing activity | BOWERS CYRIL Y (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1159292-A2 | COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | Administrators of The Tulane Educational Fund (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001007409-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA UK LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000009537-A2 | COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | L3MBTL3 723/4885L3MBTL1 449/4885MBTD1 1000/4885 |
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | L3MBTL3 2807/4885L3MBTL1 2023/4885MBTD1 916/4885 |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | L3MBTL3 4672/4885L3MBTL1 4723/4885MBTD1 3453/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | L3MBTL3 2807/4885L3MBTL1 2023/4885MBTD1 916/4885 |
| US-20020151501-A1 | Compounds having growth hormone releasing activity | GHSR, GHRHR, NPY1R | L3MBTL3 3028/4885L3MBTL1 2502/4885MBTD1 2040/4885 |
| US-12269793-B2 | Affinity illudofulvene conjugates | OGFR, TNFSF11, FCER2 | L3MBTL3 723/4885L3MBTL1 449/4885MBTD1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.